International Journal of Gerontology
Volume 1, Issue 1 , Pages 2-9, March 2007

HB-EGF, Transactivation, and Cardiac Hypertrophy

  • Seiji Takashima

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine and Health Care Center, Osaka University, Osaka, Japan
  • ,
  • Masafumi Kitakaze

      Affiliations

    • Cardiovascular Division of Medicine, National Cardiovascular Center of Japan, Suita, Osaka, Japan
    • Corresponding Author InformationCorrespondence to: Dr Masafumi Kitakaze, Cardiovascular Division of Medicine, National Cardiovascular Center of Japan, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan

Accepted 1 December 2006.

SUMMARY 

Transactivation of epidermal growth factor receptor (EGFR) family ligands by G protein coupled receptor (GPCR) agonist plays important roles in many physiologic activities. In the heart, heparin-binding EGF-like growth factor (HB-EGF), which is one of the EGF family ligands, is an indispensable molecule for cardiac cell metabolism. Membrane-anchored HB-EGF is released by GPCR agonist stimulation and moves signals leading to hypertrophy. Amelioration of this signal transduction by HB-EGF genome deletion causes severe heart dysfunction, indicating the important role of HB-EGF in the heart. Cleavage of HB-EGF was mediated by activation of membrane-anchored metalloprotease. Inhibitor of metalloprotease prevents activation of HB-EGF andattenuates hypertrophic response of cardiomyocytes by GPCR agonists such as angiotensin II or catecholamine. These data strongly suggest that HB-EGF is involved in cardiac development and metabolism. The physiologicand clinical roles of EGF family ligands in the heart are reviewed.

Key Words:  cardiac hypertrophy , heart failure , HB-EGF , metalloprotease

No full text is available. To read the body of this article, please view the PDF online.

 

PII: S1873-9598(08)70018-8

doi:10.1016/S1873-9598(08)70018-8

International Journal of Gerontology
Volume 1, Issue 1 , Pages 2-9, March 2007